Literature DB >> 31981999

Drugging histone methyltransferases in cancer.

Laia Richart1, Raphaël Margueron2.   

Abstract

Targeting chromatin-modifying enzymes is a promising strategy for cancer treatment. The antitumor effectivity of compounds inhibiting histone methyltransferases - mainly EZH2 - is currently being tested in phase I/II clinical trials, some of them showing positive results in hematological malignancies and solid tumors of specific mutational background. In this review, we aim at highlighting the recent advances in the field of histone methyltransferase inhibitors and describing the challenges that need to be addressed for their successful implementation in the clinics.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; EZH2; Epidrugs; Histone methyltransferases; PRC2

Mesh：

Substances：

Year:  2020        PMID： 31981999     DOI： 10.1016/j.cbpa.2019.11.009

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN： 1367-5931            Impact factor:   8.822


  16 in total

1.  Detection and Quantification of Histone Methyltransferase Activity In Vitro.

Authors:  Nwamaka J Idigo; Philipp Voigt
Journal:  Methods Mol Biol       Date:  2022

2.  S100A11 activates the pentose phosphate pathway to induce malignant biological behaviour of pancreatic ductal adenocarcinoma.

Authors:  Xue Zeng; Hong Guo; Zhuang Liu; Zilan Qin; Yuyang Cong; Naihan Ren; Yuxiang Zhang; Na Zhang
Journal:  Cell Death Dis       Date:  2022-06-25       Impact factor: 9.685

3.  NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.

Authors:  Yiannis Drosos; Jacquelyn A Myers; Beisi Xu; Kaeli M Mathias; Emma C Beane; Sandi Radko-Juettner; Robert J Mobley; Margaret E Larsen; Federica Piccioni; Xiaotu Ma; Jonathan Low; Baranda S Hansen; Samuel T Peters; Natarajan V Bhanu; Sandeep K Dhanda; Taosheng Chen; Santhosh A Upadhyaya; Shondra M Pruett-Miller; David E Root; Benjamin A Garcia; Janet F Partridge; Charles W M Roberts
Journal:  Mol Cell       Date:  2022-05-09       Impact factor: 19.328

4.  Sox2-Evf2 lncRNA-mediated mechanisms of chromosome topological control in developing forebrain.

Authors:  Ivelisse Cajigas; Abhijit Chakraborty; Madison Lynam; Kelsey R Swyter; Monique Bastidas; Linden Collens; Hao Luo; Ferhat Ay; Jhumku D Kohtz
Journal:  Development       Date:  2021-03-15       Impact factor: 6.868

Review 5.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

Review 6.  DNA Methylation Dysfunction in Chronic Kidney Disease.

Authors:  Diego Ingrosso; Alessandra F Perna
Journal:  Genes (Basel)       Date:  2020-07-16       Impact factor: 4.096

7.  Polycomb repressor complex 2 function in breast cancer (Review).

Authors:  Courtney J Martin; Roger A Moorehead
Journal:  Int J Oncol       Date:  2020-09-17       Impact factor: 5.650

8.  Molecular profiling of epigenetic landscape of cancer cells during extracellular matrix detachment.

Authors:  Mohammad Imran Khan; Mazin A Zamzami; Aftab Ahmad; Hani Choudhry
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

Review 9.  The Epigenetic Profile of Tumor Endothelial Cells. Effects of Combined Therapy with Antiangiogenic and Epigenetic Drugs on Cancer Progression.

Authors:  Oskar Ciesielski; Marta Biesiekierska; Baptiste Panthu; Varvara Vialichka; Luciano Pirola; Aneta Balcerczyk
Journal:  Int J Mol Sci       Date:  2020-04-09       Impact factor: 5.923

10.  KRAB domain of ZFP568 disrupts TRIM28-mediated abnormal interactions in cancer cells.

Authors:  Janani Kumar; Gundeep Kaur; Ren Ren; Yue Lu; Kevin Lin; Jia Li; Yun Huang; Anamika Patel; Michelle C Barton; Todd Macfarlan; Xing Zhang; Xiaodong Cheng
Journal:  NAR Cancer       Date:  2020-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.